Comparative Pharmacology
Head-to-head clinical analysis: MINITRAN versus NITROGLYCERIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINITRAN versus NITROGLYCERIN IN DEXTROSE 5.
MINITRAN vs NITROGLYCERIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing cGMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels and causing venous and arterial dilation.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
None Documented
None Documented
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator